{"entity":{"id":"cyh33","kind":"drug","name":"CYH33","aka":[],"tldr":"CYH33 is a small-molecule inhibitor from Haihe Biopharma Co., Ltd., in registered phase 2 trials for ovarian cancer.","summary":"CYH33 is listed on ClinicalTrials.gov as an intervention in 1 registered phase 2 trial sponsored by Haihe Biopharma Co., Ltd., in ovarian cancer. Described in the registry record as a small-molecule inhibitor; the trial entries below carry the sponsor's wording. OnCo records the agent from the registry alone; approvals, results and the sponsor's own description will follow as they are published.","status":"phase-2","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov: trials of CYH33","url":"https://clinicaltrials.gov/search?intr=CYH33"}],"tags":["pipeline","ctgov-ingest","registry-only"],"related":[],"cancers":["ovarian"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":["haihe-biopharma"],"institutions":[],"pathways":[],"terms":[],"trials":["nct05043922"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"provenance":{"editedBy":"OnCo ingestion (ClinicalTrials.gov v2, registry-only)","editedOn":"2026-09-16"},"code":"CYH33","modality":"Small-molecule inhibitor","mechanism":"Described in the registry record as a small-molecule inhibitor; the trial entries below carry the sponsor's wording.","approvals":[],"mechanismSteps":[],"toxicity":[],"access":[],"regulatoryEvents":[]},"route":"/drugs/cyh33/","neighbours":{"cancer":[{"id":"ovarian","kind":"cancer","name":"Ovarian cancer","route":"/cancers/ovarian/"}],"company":[{"id":"haihe-biopharma","kind":"company","name":"Haihe Biopharma","route":"/companies/haihe-biopharma/"}],"trial":[{"id":"nct05043922","kind":"trial","name":"A Study to Evaluate the Efficacy and Safety of CYH33 in Patients With Recurrent/Persistent Ovary Clear Cell Carcinoma","route":"/trials/nct05043922/"}]}}